AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31319970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression
Number of subjects: 71
Study 31319970 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 71
Study 31319970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 71
Study 31319970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide in limited disease (LD)
Number of subjects: 71
Study 31319970 — intervention group
Group type: COMPARATOR
Intervention: Observation in limited disease (LD)
Number of subjects: 71
Study 31319970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide in extensive disease (ED)
Number of subjects: 71
Study 31319970 — intervention group
Group type: COMPARATOR
Intervention: Observation in extensive disease (ED)
Number of subjects: 71
Study 29084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-related counseling during primary care visits
Number of subjects: 535
Study 26955809 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy (15 fractions of 2.4 Gy combined with gemcitabine 1,000 mg/m² on days 1, 8, and 15)
Number of subjects: 244
Study 26955809 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy after resection (four cycles in arm B)
Number of subjects: 244
Study 26955809 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 244
Study 26955809 — intervention group
Group type: COMPARATOR
Intervention: Direct explorative laparotomy (control group)
Number of subjects: 244
Study 26955809 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy after resection (six cycles in arm A)
Number of subjects: 244
Study 25267523 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 1,250 pulses/d)
Number of subjects: 21
Study 25267523 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study 23146809 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention and comprehensive rehabilitation training
Number of subjects: 120
Study 23146809 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard drug therapy, medical basic nursing, and conventional nursing)
Number of subjects: 120
Study 19820080 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg (S50) bid
Number of subjects: 39
Study 19820080 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg (F250)/S50 bid
Number of subjects: 39
Study 19820080 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg (F100)/S50
Number of subjects: 39
Study 18046673 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 18046673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16242550 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT removal at the time of tracheal extubation
Number of subjects: 40
Study 16242550 — intervention group
Group type: COMPARATOR
Intervention: NGT maintenance until the passage of flatus
Number of subjects: 40
Study 12174789 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-dose ivermectin treatment
Number of subjects: 0
Study 12174789 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ivermectin treatment
Number of subjects: 0
Study 12174789 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual ivermectin treatment
Number of subjects: 0
Study 12174789 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly ivermectin treatment
Number of subjects: 0
Study 12174789 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization's African Programme for Onchocerciasis Control
Number of subjects: 0
Study 10442366 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus calcium folinate administered three times per day for 21 days in combination with paclitaxel
Number of subjects: 14
Study 8553416 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempters
Number of subjects: 1050
Study 8553416 — intervention group
Group type: COMPARATOR
Intervention: Depressed/suicide ideators
Number of subjects: 1050
Study 8553416 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed adolescents
Number of subjects: 1050
Study 2150907 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospectomycin sulfate (U‐63,366F) 1,000 mg
Number of subjects: 96
Study 2150907 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (Control)
Number of subjects: 96
Study 508127 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to four 25-mg tablets per day)
Number of subjects: 100
Study 508127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31987547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance/Movement Training (DMT)
Number of subjects: 62
Study 31987547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 62
Study 31987547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 31004521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy/Borkovec's treatment package
Number of subjects: 75
Study 31004521 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy
Number of subjects: 75
Study 31004521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy/Acceptance‐based behavioral therapy
Number of subjects: 75
Study 28011248 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% probability of receiving an antiemetic
Number of subjects: 48
Study 28011248 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% probability of receiving an antiemetic
Number of subjects: 48
Study 28011248 — intervention group
Group type: COMPARATOR
Intervention: 0% probability of receiving an antiemetic
Number of subjects: 48
Study 28011248 — intervention group
Group type: COMPARATOR
Intervention: Inert substance (control for all groups)
Number of subjects: 48
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group (levobupivacaine 0.5% every 6 h)
Number of subjects: 80
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion group (levobupivacaine 0.25% at 5 ml/h)
Number of subjects: 80
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT with bolus
Number of subjects: 80
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT with continuous infusion
Number of subjects: 80
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: POST with bolus
Number of subjects: 80
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: POST with continuous infusion
Number of subjects: 80
Study 24966147 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all cases)
Number of subjects: 80
Study 24966147 — intervention group
Group type: COMPARATOR
Intervention: ANT vs POST
Number of subjects: 80
Study 23617259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 80
Study 23617259 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 80
Study 21900585 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 50,000 IU intravenous bolus prior to PPCI and another bolus 24 hours later (n=26)
Number of subjects: 51
Study 21900585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 51
Study 18954400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and topical anesthetic
Number of subjects: 100
Study 18954400 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound and placebo anesthetic
Number of subjects: 100
Study 16457894 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR*D trial intervention strategies
Number of subjects: 4041
Study 16457894 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR*D trial ethical and procedural strategies
Number of subjects: 4041
Study 12679945 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 135
Study 12679945 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 135
Study 12679945 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 135
Study 10634454 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride therapy, 5 mg/d for 6 weeks
Number of subjects: 60
Study 10634454 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 60
Study 8957200 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial treatment programme (non-pharmacological treatment with possible drug therapy)
Number of subjects: 0
Study 8957200 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 1382156 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 1382156 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 1382156 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 1382156 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 1382156 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 1382156 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 3553482 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride + Salbutamol
Number of subjects: 118
Study 3553482 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride + Placebo
Number of subjects: 118
Study 3553482 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + Placebo
Number of subjects: 118
Study 3553482 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + Placebo
Number of subjects: 118
Study 31653884 — intervention group
Group type: EXPERIMENTAL
Intervention: New Corvis ST parameters in keratoconus eyes
Number of subjects: 154
Study 31653884 — intervention group
Group type: COMPARATOR
Intervention: New Corvis ST parameters in normal eyes
Number of subjects: 154
Study 31653884 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTh and CBI
Number of subjects: 154
Study 31324936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 3
Study 31324936 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 3
Study 31324936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 27145355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (8-week program)
Number of subjects: 43
Study 27145355 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm
Number of subjects: 43
Study 27145355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Number of subjects: 43
Study 25728739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of desmopressin (ODM) - Group B: 240 μg ODM per day → 120 μg ODM per day → 120 μg ODM per alternate day → cessation
Number of subjects: 157
Study 25728739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of desmopressin (ODM) - Group C: 240 μg ODM per day → 120 μg ODM per day → 60 μg ODM per day → 60 μg ODM per alternate day → cessation
Number of subjects: 157
Study 23870444 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum-based measurement (CBM)
Number of subjects: 413
Study 23870444 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher ratings using Performance Screening Guides (PSGs)
Number of subjects: 413
Study 23870444 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Screening Guides (PSGs)
Number of subjects: 413
Study 23870444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both screening methods (CBM and PSGs)
Number of subjects: 413
Study 21460676 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable poly-L-lactic acid
Number of subjects: 233
Study 21460676 — intervention group
Group type: COMPARATOR
Intervention: Human collagen
Number of subjects: 233
Study 19778676 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal reduction
Number of subjects: 25
Study 19778676 — intervention group
Group type: COMPARATOR
Intervention: HOCM patients
Number of subjects: 25
Study 19778676 — intervention group
Group type: COMPARATOR
Intervention: HCM patients
Number of subjects: 25
Study 19778676 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 25
Study 16945890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling + subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20
Study 16945890 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling + subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20
Study 16945890 — intervention group
Group type: COMPARATOR
Intervention: Subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20
Study 16945890 — intervention group
Group type: COMPARATOR
Intervention: Subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20
Study 15238098 — intervention group
Group type: EXPERIMENTAL
Intervention: New topical formulation (0.25% alpha-glucosylrutin, 1% tocopheryl acetate, SPF 15 sunscreen)
Number of subjects: 30
Study 15238098 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen-only gel
Number of subjects: 30
Study 15238098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11174807 — intervention group
Group type: EXPERIMENTAL
Intervention: Aorto-uni-iliac endograft (A-I)
Number of subjects: 121
Study 11174807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated endograft (BI)
Number of subjects: 121
Study 11174807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube endograft (T)
Number of subjects: 121
Study 11174807 — intervention group
Group type: COMPARATOR
Intervention: Open control (C)
Number of subjects: 121
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative donor and recipient
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative donor and seropositive recipient
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive donor and recipient
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive donor and seronegative recipient
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransplantation
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of units of blood products administered during transplantation
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CMV disease
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive fungal disease
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 146
Study 9036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor and recipient CMV serologic status
Number of subjects: 146
Study 7932425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone, 1000 mg nightly
Number of subjects: 52
Study 7932425 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, 250 mg twice daily
Number of subjects: 52
Study 7932425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 52
Study 7932425 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 52
Study 3278942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g 5-aminosalicylic acid enemas
Number of subjects: 25
Study 3278942 — intervention group
Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 25
Study 3278942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g 5-aminosalicylic acid enemas (second trial)
Number of subjects: 25
Study 3278942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second trial)
Number of subjects: 25
Study 30952534 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetic participants
Number of subjects: 5792
Study 30952534 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic participants
Number of subjects: 5792
Study 30952534 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic participants
Number of subjects: 5792
Study 31507253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive short-term dynamic psychotherapy (30-day inpatient program)
Number of subjects: 62
Study 31507253 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 62
Study 27546011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 272
Study 27546011 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-only
Number of subjects: 272
Study 24753507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 20
Study 24753507 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 23766412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron combined with 75 µg/kg midazolam (Group RM)
Number of subjects: 100
Study 23766412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron (Group R)
Number of subjects: 100
Study 23766412 — intervention group
Group type: COMPARATOR
Intervention: 75 µg/kg midazolam (Group M)
Number of subjects: 100
Study 22043673 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial needling at corresponding myofascial fasciae trigger point (MTrP) followed by acupuncture at Jiaji (EX‐B 2) for 30 min.
Number of subjects: 60
Study 22043673 — intervention group
Group type: COMPARATOR
Intervention: Superficial needling only (control group).
Number of subjects: 60
Study 18504090 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose immediate-release morphine (DD)
Number of subjects: 19
Study 18504090 — intervention group
Group type: COMPARATOR
Intervention: Single-dose immediate-release morphine (SD)
Number of subjects: 19
Study 16388973 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) in addition to best medical treatment
Number of subjects: 120
Study 16388973 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 120
Study 16388973 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120
Study 15130906 — intervention group
Group type: COMPARATOR
Intervention: Smokers with > 10 pack-years
Number of subjects: 232
Study 15130906 — intervention group
Group type: COMPARATOR
Intervention: Smokers with > 20 pack-years
Number of subjects: 232
Study 15130906 — intervention group
Group type: COMPARATOR
Intervention: Smokers with > 30 pack-years and DL(CO) < 60% predicted
Number of subjects: 232
Study 15130906 — intervention group
Group type: COMPARATOR
Intervention: Smokers with early stages of smoking-induced lung disease
Number of subjects: 232
Study 15130906 — intervention group
Group type: COMPARATOR
Intervention: Smokers with advanced stages of smoking-induced lung disease
Number of subjects: 232
Study 11117501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized visual task
Number of subjects: 6
Study 11117501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized motor task
Number of subjects: 6
Study 11117501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized visual and motor tasks
Number of subjects: 6
Study 9187599 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest radiographs
Number of subjects: 80
Study 7506162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 46
Study 7506162 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 46
Study 3070611 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. naloxone (20 mg, 40 mg)
Number of subjects: 20
Study 3070611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28985265 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (n = 229) involving early coronary angiography, with immediate evaluation for percutaneous coronary intervention, coronary artery bypass graft, optimal medical therapy.
Number of subjects: 457
Study 28985265 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (n = 228).
Number of subjects: 457
Study 26690634 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol prime (0.6 g of alcohol per kg of body weight)
Number of subjects: 60
Study 26690634 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink manipulated to smell and taste alcoholic
Number of subjects: 60
Study 25910919 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine (3.75μg of hemagglutinin antigen, two doses given 21 days apart)
Number of subjects: 81
Study 25910919 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 81
Study 25910919 — intervention group
Group type: COMPARATOR
Intervention: TIV (licensed seasonal inactivated trivalent influenza vaccine)
Number of subjects: 81
Study 23994934 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (5 ml, 200 mg daily for 4 weeks)
Number of subjects: 30
Study 15782622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b (Peg‐IFN‐alpha2b) plus ribavirin
Number of subjects: 64
Study 15782622 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte interferon alpha (IFN‐alpha) plus ribavirin
Number of subjects: 64
Study 15782622 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR at week 4
Number of subjects: 64
Study 15782622 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR after more than 4 weeks of therapy
Number of subjects: 64
Study 12701935 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily doses of inhaled corticosteroids (iCSTs) (>= 400 microg)
Number of subjects: 97
Study 12701935 — intervention group
Group type: COMPARATOR
Intervention: Emergency department visits
Number of subjects: 97
Study 12701935 — intervention group
Group type: COMPARATOR
Intervention: Total asthma-related costs
Number of subjects: 97
Study 10214535 — intervention group
Group type: EXPERIMENTAL
Intervention: zolmitriptan 5 mg
Number of subjects: 24
Study 10214535 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine 15 mg
Number of subjects: 24
Study 10214535 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24